PROGRAMMATIC LEARNING OBJECTIVES
As an attendee of MAD-ID 2017, you will be able to earn up to 18 Continuing Pharmacy Education hours (1.8 CEU) or 17.5 Continuing Medical Education hours (AMA PRA Category 1 Credits™). At the conclusion of this activity, you should be able to:
Depending on which four classroom/workshop sessions the participant attends, four of the following six learning objectives should be achieved:
1. List three ways in which “smart” data retrieval/management systems can be used to facilitate stewardship programs and prioritize them for your own institution/program.
2. Propose and defend a behavioral modification technique aimed at optimizing antimicrobial use and that would be appropriate to your practice area.
3. Explain the basic tenets of antibiogram construction and dissemination and list two ways antibiogram data can be analyzed and used to optimize empiric therapy.
4. List three examples of readily achievable stewardship goals (“low hanging fruit”) and explain how to best organize and present such results in a manner that justifies the costs of a stewardship program.
5. List three or more criteria that must be judged in assessing the quality of a published article addressing an infectious disease therapeutic or stewardship topic.
6. List three or more well-described and effective stewardship initiatives that can be implemented with limited financial and/or personnel resources.
The following learning objective relate to the remaining educational sessions:
7. Explain, using existing evidence, how antimicrobial stewardship is a major activity that can effectively help to address the challenges of microbial resistance.
8. Summarize current therapeutic recommendations, based on current national or international guidelines, for empiric and definitive treatment of community- and hospital-acquired pneumonia.
9. Provide an overview of the natural state and function of the microbiome and how antibiotic therapy changes and compromises its natural beneficial properties.
10. Discuss the nature and extent of the burden of antimicrobial adverse events and methods for minimizing their occurrence using pharmacodynamic principles.
11. Describe those issues of basic susceptibility testing and interpretation of break points that would enhance our understanding and application of these basic concepts to selection, dosing and use of antimicrobials.
12. Summarize arguments for and against continued use of vancomycin for serious methicillin-resistant Staphylococcus aureus infections in the context of existing evidence, for and against, as well as likely changes in the upcoming, updated vancomycin dosing/monitoring consensus statement.
13. Apply current knowledge to develop dosing recommendations for antibiotic use in patients who are obese and/or critically ill.
14. Explain the nuances of antimicrobial stewardship in regard to use of antifungal agents, especially in the context of antifungal resistance.
15. List and summarize the application stewardship principles and initiatives in the setting of long-term care facilities.